BEYOND THE BLUE:

What Fellows Are Reading in Other Journals

Can We DAMPen the Cross-Talk between the Lung and Kidney in the ICU?

Mark L. Hepokoski, Amy L. Bellinghausen, Christine M. Bojanowski, and Atul Malhotra

Division of Pulmonary and Critical Care Medicine, University of California San Diego, San Diego, California

Recommended Reading from University of California, San Diego Division of Pulmonary and Critical Care Medicine Fellows; Atul Malhotra, M.D., Chief of Research and Faculty Advisor

Chawla L, et al. Impact of Acute Kidney Injury in Patients Hospitalized with Pneumonia. *Crit Care Med* (1)

Reviewed by Mark L. Hepokoski

Preclinical and clinical studies have demonstrated multiple relevant lung–kidney interactions (2, 3). For example, chronic obstructive pulmonary disease and ventilator-induced lung injury promote endothelial inflammation in the lung and kidney (2, 4). Furthermore, the development of renal injury in patients with pulmonary disease is important clinically, as acute kidney injury (AKI) is associated with increased mortality and poor long-term functional outcomes (5). In this study, Chawla and colleagues hypothesized that patients with combined AKI and pneumonia would have a higher incidence of mortality and permanent renal dysfunction after hospitalization than patients with AKI or pneumonia alone (1).

This was a retrospective analysis from a Veterans Affairs database that included 54,894 hospitalized patients. The authors compared three groups on the basis of International Classification of Diseases, Ninth Revision codes, including those with AKI (8,437, 15.4%), pneumonia (33,067, 60.2%), and AKI with pneumonia (13,390, 24.4%). The primary endpoint was a composite of major adverse kidney events after discharge, defined as a permanent 25% decrease in estimated glomerular filtration rate from baseline, need for chronic dialysis, and death. They observed that the patients with pneumonia with AKI had the highest mortality (3,168 [37.6%] vs. 14,114 [42.7%] vs. 6,867 [51.3%]; all $P < 0.0001$) and major adverse kidney events after discharge (AKI, 4,434 [52.6%] vs. pneumonia, 15,825 [47.9%] vs. AKI with pneumonia, 8,262 [61.7%]; all $P < 0.0001$).

The excess mortality as a function of number of organ failures is not surprising. However, what brings novelty to this study was the observation that postdischarge outcomes are worse when

AKI accompanies pneumonia than AKI or pneumonia alone. These findings are particularly critical with increasing emphasis on AKI recovery and post-ICU syndromes (6). The mechanisms of pneumonia-induced kidney failure are unclear but point to the need for further research into lung–kidney cross-talk. For example, future studies could focus on remote organ complications of pneumonia as a means to improve outcomes.

The results presented may have been overestimated, as the authors were unable to identify severity of illness on the basis of the provided International Classification of Diseases, Ninth Revision codes. However, these data clearly advance the field of lung–kidney interactions, and we are excited by the progress being made. Novel strategies aimed at mitigating detrimental cross-talk between the lung and kidney have great potential to improve short- and long-term outcomes in critically ill patients. Only by further investigation into mechanisms of organ cross-talk are new therapeutic approaches likely to emerge. ■

References

1. Chawla LS, Amdur RL, Faselis C, Li P, Kimmel PL, Palant CE. Impact of acute kidney injury in patients hospitalized with pneumonia. *Crit Care Med* 2017;45:600–606.
2. Hepokoski M, Englert JA, Baron RM, Crotty-Alexander LE, Fuster MM, Beitler JR, et al. Ventilator-induced lung injury increases expression of endothelial inflammatory mediators in the kidney. *Am J Physiol Renal Physiol* 2017;312:F654–F660.
3. Husain-Syed F, Slutsky AS, Ronco C. Lung-kidney cross-talk in the critically ill patient. *Am J Respir Crit Care Med* 2016;194:402–414.
4. Polverino F, Laucha-Contreras ME, Petersen H, Bijol V, Sholl LM, Choi ME, et al. A pilot study linking endothelial injury in lungs and kidneys in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2017;195:1464–1476.
5. Chawla LS, Amdur RL, Shaw AD, Faselis C, Palant CE, Kimmel PL. Association between AKI and long-term renal and cardiovascular outcomes in United States veterans. *Clin J Am Soc Nephrol* 2014;9:448–456.

(Received in original form December 22, 2017; accepted in final form August 27, 2018)

Supported by NIH grants R01 HL085188, K24 HL132105, T32 HL134632, R21 HL121794, R01 HL 119201, and R01 HL081823 (A.M.). ResMed, Inc., provided a philanthropic donation to the University of California San Diego in support of a sleep center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Correspondence and requests for reprints should be addressed to Atul Malhotra, M.D., University of California San Diego, Pulmonary, Critical Care, and Sleep Medicine, 9300 Campus Point Drive, #7381, La Jolla, CA 92037. E-mail: amalhotra@ucsd.edu.

Am J Respir Crit Care Med Vol 198, Iss 9, pp 1220–1222, Nov 1, 2018

Copyright © 2018 by the American Thoracic Society

Originally Published in Press as DOI: 10.1164/rccm.201712-2573RRR on August 28, 2018

Internet address: www.atsjournals.org

6. Kellum JA, Sileanu FE, Bihorac A, Hoste EA, Chawla LS. Recovery after acute kidney injury. *Am J Respir Crit Care Med* 2017;195:784–791.

Krychtiuk KA, et al. Mitochondrial DNA and Toll-Like Receptor-9 Are Associated with Mortality in Critically Ill Patients. *Crit Care Med* (7)

Reviewed by Amy L. Bellinghausen

Mitochondria, whose origins are as unicellular organisms, are known to release molecules that activate the innate immune system during cellular injury (8). These molecules are detected by toll-like receptors, similar to the process of detecting bacterial antigens. For example, extracellular mitochondrial DNA (mtDNA) fragments have been shown to potentiate systemic inflammation via toll-like receptor 9 (TLR9), and circulating mtDNA levels correlate with lung and kidney injury and ICU mortality (9, 10). Krychtiuk and colleagues sought to investigate further the causative role of mtDNA in organ failures by investigating if plasma mtDNA is more predictive of mortality when associated with increased TLR9 expression (7).

In this single-center, prospective observational study, blood was sampled from 228 consecutive patients within the first 24 hours of admission to an academic ICU in Austria. Samples were analyzed for total copy number of mtDNA using quantitative real-time polymerase chain reaction targeting mtDNA-specific primers as well as TLR9 expression in circulating monocytes using flow cytometry (mean fluorescence intensity). Blood from 20 healthy control subjects was also collected. Investigators used multivariate analyses to assess the impact of mtDNA and TLR9 expression on 30-day mortality. As anticipated, levels of plasma mtDNA were significantly higher in ICU patients than in healthy control subjects (24.1 ng/ml; interquartile range [IQR], 10.7–42.6 ng/ml; vs. 13.8 ng/ml; IQR, 6.5–28.5 ng/ml; $P < 0.05$). Furthermore, mtDNA levels had predictive value beyond Acute Physiology and Chronic Health Evaluation II, as demonstrated by an elevated C-statistic, suggesting that mtDNA may be an independent prognostic indicator. Also noted were higher levels of mtDNA in nonsurvivors (26.9 ng/ml; IQR, 11.2–60.6 ng/ml; vs. 19.7 ng/ml; IQR, 9.5–34.8 ng/ml; $P < 0.05$), an effect that appears to be mediated by TLR9 (only patients with elevated levels of TLR9 expression showed a correlation between elevated mtDNA and mortality). These findings point to a potential role of TLR9-associated inflammation in mediating death in patients with elevated circulating mtDNA levels.

A potential limitation to generalizability is that the most common diagnosis in the ICU population studied was cardiopulmonary resuscitation, followed by heart failure and cardiac surgery, representing a group that may differ from that of many medical ICUs. However, other studies have demonstrated similar findings of elevated mtDNA in a variety of critically ill populations (11). Although unable to establish a causal link, this study suggests that mitochondrial injury and release of mtDNA into the circulation may be a key part of the final common pathway for inflammation and mortality in multiple organ failure syndromes. ■

References

7. Krychtiuk KA, Ruhittel S, Hohensinner PJ, Koller L, Kaun C, Lenz M, et al. Mitochondrial DNA and toll-like receptor-9 are associated with mortality in critically ill patients. *Crit Care Med* 2015;43:2633–2641.

8. Zhang Q, Raoof M, Chen Y, Sumi Y, Sursal T, Junger W, et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. *Nature* 2010;464:104–107.
9. Hotz MJ, Qing D, Shashaty MGS, Zhang P, Faust H, Sondheimer N, et al. Red blood cells homeostatically bind mitochondrial DNA through TLR9 to maintain quiescence and to prevent lung injury. *Am J Respir Crit Care Med* 2018;197:470–480.
10. Nakahira K, Kyung SY, Rogers AJ, Gazourian L, Youn S, Massaro AF, et al. Circulating mitochondrial DNA in patients in the ICU as a marker of mortality: derivation and validation. *PLoS Med* 2013;10:e1001577. [Discussion, p. e1001577].
11. Boyapati RK, Tamborska A, Dorward DA, Ho GT. Advances in the understanding of mitochondrial DNA as a pathogenic factor in inflammatory diseases. *F1000 Res* 2017;6:169.

Simmons JD, et al. Mitochondrial DNA Damage Associated Molecular Patterns in Ventilator-associated Pneumonia: Prevention and Reversal by Intratracheal DNase I. *J Trauma Acute Care Surg* (12)

Reviewed by Christine M. Bojanowski

Ventilator-associated pneumonia (VAP) remains a common diagnostic and treatment challenge. Recent studies have shown that extracellular mtDNA released from injured cells during oxidant stress or bacterial infection may represent a novel mechanism of injury yielding a potential therapeutic target (13). In the lung, mtDNA is known to function as damage-associated molecular patterns (DAMPs) that cause endothelial barrier injury and pulmonary edema (14, 15). In this translational study, Simmons and colleagues (12) aimed to assess the use of intratracheal DNase in the prevention and treatment of VAP, with the hypothesis being that the administration of intratracheal DNase would enhance the clearance of mtDNA. Importantly, DNase is already U.S. Food and Drug Administration approved as a mucolytic in cystic fibrosis and thus may be readily implemented in the ICU.

Accordingly, the investigators used a ventilated rat model to determine if the use of DNase prevented or reversed DAMP-induced lung injury. Intratracheal *Pseudomonas aeruginosa* (PA 103) significantly increased both the amount of perfusate mtDNA DAMPs (ng/ml) and degree of lung injury as suggested by vascular filtration coefficient (Kf, expressed as ml/min/cm H₂O/100 g.). Intratracheal DNase administration was effective in both prevention and reversal experiments on the basis of the significant reduction of mtDNA DAMPs (18.9 ± 2.6 vs. 3.0 ± 0.2 and 39.9 ± 6.3 vs. 11.5 ± 3.8 ; $P < 0.05$) and Kf (0.73 ± 0.2 vs. 0.20 ± 0.01 and 1.29 ± 0.05 vs. 0.18 ± 0.003 ; $P < 0.05$).

The investigators then prospectively enrolled consecutive patients ($n = 31$) admitted to the ICU who were suspected to have VAP. DAMPs were measured from BAL fluid and serum at the time of suspected diagnosis, with serum levels measured again at 24 to 48 hours. Patients with culture-positive VAP had significantly higher mtDNA DAMPs in both the BAL fluid and the serum at 24 hours than those without VAP (248.70 ± 109.7 vs. 43.91 ± 16.61 , $P < 0.05$; and 159.60 ± 77.37 vs. 10.43 ± 4.36 , $P < 0.05$; respectively).

This intriguing study reveals the association between bacterial pneumonia and the accumulation of mtDNA DAMPs in both the lung and serum in humans. In their preclinical model, this study also suggests the potential role of DNase in the prevention and treatment of VAP. We would speculate that a decrease in the total concentration of circulating mtDNA may also occur after DNase therapy and could

theoretically influence the risk of remote organ failures, such as AKI, in patients with VAP. We support further basic and clinical research regarding the role of mtDNA DAMPs in the ICU. ■

Author disclosures are available with the text of this article at www.atsjournals.org.

References

12. Simmons JD, Freno DR, Muscat CA, Obiako B, Lee YL, Pastukh VM, *et al*. Mitochondrial DNA damage associated molecular patterns in ventilator-associated pneumonia: prevention and reversal by intratracheal DNase I. *J Trauma Acute Care Surg* 2017;82:120–125.
 13. Maeda A, Fadeel B. Mitochondria released by cells undergoing TNF- α -induced necroptosis act as danger signals. *Cell Death Dis* 2014;5:e1312.
 14. Chouteau JM, Obiako B, Gorodnya OM, Pastukh VM, Ruchko MV, Wright AJ, *et al*. Mitochondrial DNA integrity may be a determinant of endothelial barrier properties in oxidant-challenged rat lungs. *Am J Physiol Lung Cell Mol Physiol* 2011;301:L892–L898.
 15. Kuck JL, Obiako BO, Gorodnya OM, Pastukh VM, Kua J, Simmons JD, *et al*. Mitochondrial DNA damage-associated molecular patterns mediate a feed-forward cycle of bacteria-induced vascular injury in perfused rat lungs. *Am J Physiol Lung Cell Mol Physiol* 2015;308:L1078–L1085.
-